Radius Health (RDUS) Stock Rating Lowered by ValuEngine
Radius Health (NASDAQ:RDUS) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Thursday.
Other analysts have also issued research reports about the stock. BidaskClub upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Morgan Stanley upped their target price on shares of Radius Health from $57.00 to $61.00 and gave the stock an “overweight” rating in a research note on Friday, March 2nd. Cantor Fitzgerald set a $58.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research note on Thursday, March 22nd. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Finally, Leerink Swann assumed coverage on shares of Radius Health in a research note on Thursday, March 29th. They issued an “outperform” rating and a $53.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the company. Radius Health presently has an average rating of “Hold” and a consensus price target of $52.10.
Radius Health stock opened at $31.51 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.96 and a current ratio of 5.04. Radius Health has a 12-month low of $24.66 and a 12-month high of $49.16. The firm has a market cap of $1,492.01, a P/E ratio of -5.43 and a beta of 1.25.
In other news, major shareholder Growth N. V. Biotech purchased 40,000 shares of the stock in a transaction dated Thursday, April 19th. The shares were purchased at an average cost of $33.80 per share, with a total value of $1,352,000.00. Following the completion of the acquisition, the insider now owns 6,050,913 shares in the company, valued at approximately $204,520,859.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Growth N. V. Biotech purchased 80,000 shares of the stock in a transaction dated Friday, March 2nd. The stock was purchased at an average cost of $32.52 per share, for a total transaction of $2,601,600.00. Following the completion of the acquisition, the insider now owns 5,853,799 shares of the company’s stock, valued at approximately $190,365,543.48. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 245,000 shares of company stock worth $8,361,100. Insiders own 15.00% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Eversept Partners LLC bought a new position in Radius Health during the fourth quarter valued at approximately $6,179,000. Prosight Management LP bought a new position in Radius Health during the fourth quarter valued at approximately $3,495,000. Mutual of America Capital Management LLC grew its position in Radius Health by 45.6% during the fourth quarter. Mutual of America Capital Management LLC now owns 49,615 shares of the biopharmaceutical company’s stock valued at $1,576,000 after acquiring an additional 15,534 shares during the last quarter. Teacher Retirement System of Texas bought a new position in Radius Health during the fourth quarter valued at approximately $353,000. Finally, Consonance Capital Management LP bought a new position in Radius Health during the fourth quarter valued at approximately $84,168,000.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.